Hypertensive phase after a novel small-lumen non-valved drainage device: predictive factors and two-year outcomes.

PURPOSE: The hypertensive phase (HP) following the implantation of a glaucoma drainage device (GDD) is a clinical challenge. We aimed to evaluate the risk factors, clinical features, and correlation of the HP with efficacy in a cohort of glaucoma patients who received a Paul glaucoma implant (PGI).

STUDY

DESIGN

This was a single-center retrospective cohort study (Hospital Clínic of Barcelona).

METHODS

Eighty-three eyes from 71 patients who underwent implantation of a PGI were included, with follow-up extending for up to 2 years. Intraocular pressure (IOP) was measured preoperatively, and at 1 day; 1 week; and 1, 3, 6, 12, and 24 months, postoperatively. Four different success criteria were established: criterion A: IOP <21 mm Hg; criterion B: <18 mm Hg; criterion C: <15 mm Hg; criterion D: <12 mm Hg. The numbers of postoperative IOP-lowering drops, complications, characteristics related to the presence or absence of an HP, and timing of prolene stent removal, among others, were recorded.

RESULTS

We observed a total of 23 cases (27.7% with an HP). On multivariate analysis we identified younger age (P = .028) and elevated IOP 1 month after surgery (P = .001) as independent risk factors. IOPs were significantly higher (P <.05) in the HP group at 1 week and at 1, 3, and 6 months postoperatively. After 12 months of follow-up, no differences were found between the 2 groups.

CONCLUSION

The occurrence of an HP with a PGI does not seem to impact surgical success beyond 12 months postoperatively. However, further research is needed to better understand the underlying mechanisms of HP development and its clinical impact.